4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

Company Overview

4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, an inhaled gene therapy intended to deliver functional CFTR genes to the lungs of people with cystic fibrosis. These products remain investigational and have not been approved for commercial use.

Founded in 2013, 4D Molecular Therapeutics is headquartered in Emeryville, California, and conducts research and clinical development activities primarily in the United States. The company was co-founded by David Kirn, who has served as its chief executive officer, and has built its business around applying engineered AAV vectors to address diseases that may benefit from targeted gene delivery.

Key Stats

• Today's Range: $13.60 to $14.14
• 50-Day Range: $9.61 to $16.76
• 52-Week Range: $6.96 to $16.93
• Volume: 1.04 million shs
• Average Volume: 935,069 shs
• Market Capitalization: $755.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.00
• Consensus Rating: Moderate Buy

4D Molecular Therapeutics Stock Analysis - MarketRank™

4D Molecular Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 404th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

4D Molecular Therapeutics has a consensus price target of $29.00, representing about 112.1% upside from its current price of $13.67.

Amount of Analyst Coverage

4D Molecular Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($4.07) to ($4.09) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 4D Molecular Therapeutics is -5.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 4D Molecular Therapeutics is -5.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

4D Molecular Therapeutics has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.60% of the float of 4D Molecular Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

4D Molecular Therapeutics has a short interest ratio ("days to cover") of 18.55, which indicates bearish sentiment.

Change versus previous month

Short interest in 4D Molecular Therapeutics has recently decreased by 0.50%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

4D Molecular Therapeutics does not currently pay a dividend.

Dividend Growth

4D Molecular Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.31

News Sentiment

4D Molecular Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for 4D Molecular Therapeutics this week, compared to 4 articles on an average week.

Search Interest

7 people have searched for FDMT on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,743,197.00 in company stock.

Percentage Held by Insiders

7.90% of the stock of 4D Molecular Therapeutics is held by insiders.

Percentage Held by Institutions

99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/05/2026
• Investor Day 2026: 10/21/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FDMT
• CIK: 1650648
• Web: www.4dmoleculartherapeutics.com
• Phone: 510-505-2680
• Fax: N/A
• Employees: 196
• Year Founded: 2013

Price Target and Rating

• Average Price Target for 4D Molecular Therapeutics: $29.00
• High Price Target: $37.00
• Low Price Target: $17.00
• Potential Upside/Downside: +112.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$140.11 million
• Net Margins: -194.74%
• Pretax Margin: -194.74%
• Return on Equity: -41.33%
• Return on Assets: -35.90%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 8.03
• Quick Ratio: 8.03

Sales & Book Value

• Annual Sales: $85.21 million
• Price / Sales: 8.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.85 per share
• Price / Book: 1.54

Miscellaneous

• Outstanding Shares: 55,240,000
• Free Float: 50,880,000
• Market Cap: $755.13 million
• Optionable: Optionable
• Beta: 2.75